In today's article, we are going to delve into the fascinating world of Fosdagrocorat and discover everything that this theme has to offer us. From its origins to its relevance today, through all the advances and changes it has experienced over time, in this article we will thoroughly explore every aspect of Fosdagrocorat. In addition, we will learn about the opinions of experts in the field and the experiences of people who have lived closely Fosdagrocorat. So get ready to immerse yourself in a journey of knowledge and discovery that will leave you with a complete and enriching vision about Fosdagrocorat.
Clinical data | |
---|---|
Other names | PF-04171327; PF-4171327; Dagrocorat 2-(dihydrogen phosphate); Dagrocorat dihydrogen phosphate |
Drug class | Selective glucocorticoid receptor modulator |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C29H30F3N2O5P |
Molar mass | 574.537 g·mol−1 |
3D model (JSmol) | |
| |
|
Fosdagrocorat (developmental code names PF-04171327 and PF-4171327; also known as dagrocorat 2-(dihydrogen phosphate)) is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed. It is the C2 dihydrogen phosphate ester of dagrocorat, and acts as a prodrug of dagrocorat with improved pharmacokinetics. The drug reached phase II clinical trials prior to the discontinuation of its development.